Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Enoxaparin + folic acid is an investigational combination regimen studied for the prevention of recurrent miscarriage in women who test negative for antiphospholipid antibodies. The regimen consists of enoxaparin, a low molecular weight heparin (LMWH) that acts as an anticoagulant by accelerating the activity of antithrombin III to inhibit Factor Xa and thrombin, and folic acid, a B-vitamin essential for DNA synthesis and homocysteine regulation. This combination was evaluated in a randomized controlled trial led by researchers at Assiut University, which demonstrated improved pregnancy outcomes compared to folic acid alone, suggesting that LMWH may benefit women with unexplained recurrent miscarriage by addressing potential subclinical thrombotic issues or placental vascular complications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on enoxaparin + folic acid.